Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The conditions of the previously executed master services agreement support late-stage clinical manufacturing of Rhenium-186 and Reyobiq.
April 23, 2026
By: Patrick Lavery
Plus Therapeutics is initiating manufacturing activities and technology transfer with SpectronRx, under terms of a previously executed master services agreement. As a healthcare company, Plus develops and commercializes precision diagnostics and radiopharmaceuticals to treat central nervous system (CNS) cancers.
The agreement supports late-stage clinical manufacturing of Rhenium-186 and Reyobiq. The latter of those (rhenium Re186 obisbemeda) is a novel, injectable radiotherapy delivering direct, targeted, high-dose radiation in CNS tumors. Plus says its associated radioisotope, Rhenium-186, is ideal for CNS therapeutics due to short half-life, and beta and gamma energy.
The Rhenium-186 isotope is currently supplied by Telix Pharmaceuticals. In the agreement with Plus, SpectronRx will serve as a second good manufacturing practice (GMP) manufacturing site alongside Radiomedix.
Regarding Reyobiq, presently, three clinical trials are evaluating its effectiveness against recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, respectively. According to Plus, Reyobiq may potentially reduce off-target risks and improve outcomes for CNS cancer patients, versus current approved therapies.
The master services agreement, as previously stated, includes a tech transfer of the Reyobiq manufacturing process. Also included in the transfer are Rhenium-186 isotope processing, analytical methods, and technical and regulatory expertise to support commercial production.
SpectronRx’s facility in Indiana will enable on-demand manufacturing of Rhenium-186 isotope production and Reyobiq drug manufacturing at a singular site.
Marc H. Hedrick, MD, President and CEO of Plus Therapeutics, said his company has a 2026 target milestone for Reyobiq. Plus would like to complete manufacturing scale-up for late-stage clinical supply needs.
“As we enter late-stage development of Reyobiq, our partnership with SpectronRx bolsters our manufacturing readiness and required expansion,” Hedrick said. “We are closely aligned with SpectronRx for best-in-class production of Reyobiq to serve the needs of the clinical community.”
Over time, Hedrick said, Plus hopes to drive growth in its radiotherapeutic business overall.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
